Drug Database
TU

tuberculosis vaccine (Mw) (Immuvac / Cadi05 / Sepsivac)

✓ Approved

Cadila Pharmaceuticals Ltd. · 细胞治疗 · 细胞治疗

什么是 tuberculosis vaccine (Mw)?

tuberculosis vaccine (Mw) 是一种细胞治疗,由Cadila Pharmaceuticals Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intradermal Injection。

药物档案

商品名Immuvac, Cadi05, Sepsivac
公司Cadila Pharmaceuticals Ltd.
药物类别细胞治疗, 疫苗
给药途径Injectable (Others), Intradermal Injection
状态Approved

治疗适应症

tuberculosis vaccine (Mw) 针对 10 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsLeprosy✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Infections and infestationsSepsis✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Infections and infestationsSystemic infection✓ Approved

注册免费账户还可查看另外 5 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedBMC infectious diseases2026-11-19

Clinical characteristics and factors associated with airflow obstruction among patients with post-tuberculosis lung disease.

Liu Jianjun J, Zhang Litong L, Zhu Tingting T, Guo Jing J

To analyze the clinical characteristics and factors associated with airflow obstruction in patients with post-tuberculosis lung disease. This retrospective cross-sectional study included 667 patients screened after successful anti-tuberculosis treatment in Lishui City between January 2024 and December 2025. Based on a post-bronchodilator forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) ratio below the lower limit of normal, participants were classified into an airflow obstruction group (n = 97) and a non-airflow obstruction group (n = 570). Symptoms were compared between the two groups, and univariate and multivariate logistic regression analyses were performed. The overall prevalence of PTLD-related airflow obsrruction is 14.5% (95% CI: 11.9%-17.2%). The frequencies of cough, sputum production, chest tightness, dyspnea, and weight loss were significantly higher in the airflow obstruction group than in the non-airflow obstruction group (p < 0.05). Univariate analysis demonstrated that age, sex, BMI, radiological score and chest CT findings including bronchiectasis, emphysema, and tuberculosis-related scarring were significantly associated with airflow obstruction following successful treatment of pulmonary tuberculosis (all p < 0.05). Multivariate logistic regression analysis identified BMI < 18.5 kg/m² (odds ratio [OR] = 9.634, 95% confidence interval [CI]: 5.187-17.892), emphysema (OR = 8.591, 95% CI: 4.084-18.069), bronchiectasis (OR = 3.750, 95% CI: 1.504-9.350),previous tuberculous pleurisy (OR = 2.678, 95% CI: 1.128-6.359), pulmonary tuberculous scars (OR = 2.184, 95% CI: 1.148-4.154) and increasing CT radiological score (OR = 1.313, 95% CI: 1.207-1.427) and age (OR = 1.031, 95% CI: 1.010-1.053) as independent factors associated with airflow obstruction (all p < 0.05). Older patients with pulmonary tuberculosis, low body mass index (BMI), extensive residual tuberculous lesions, and concurrent emphysema, bronchiectasis, tuberculous pleurisy or tuberculous scars carry a high risk of developing post-tuberculosis airflow obstruction. Early pulmonary function testing can help identify airflow limitation in this population at an early stage and enable timely intervention. Not applicable.

PMID 43052784
阅读全文 →
PubMedWellcome open research2026-11-19

Did the emergence of the Omicron variant impact the COVID-19 vaccine acceptance in the Arab world? A Twitter-based sentiment analysis.

Dimashkieh Chehab Nada N

Low vaccine acceptance constitutes a major obstacle for achieving herd immunity against coronavirus disease 2019 (COVID-19). Data on COVID-19 show a significant rise in the number of cumulative cases in Arab countries where vaccine uptake is lower than the uptake at the global level for the 2021-2022 period. The aim of this study is to analyze sentiments related to vaccine acceptance before and after the emergence of the COVID-19 Omicron variant in the Arab-speaking world. Tweets were collected before and after the Omicron emergence period in the Arab-speaking world using Python-enabled CAMeL Tools (Arabic Natural Language Processing toolkit) libraries. A sentiment analysis on COVID-19 vaccines using Arabic hashtags and a sentiment analysis by city were conducted. Two data sets pre-Omicron and post-Omicron tweets exhibited a difference in sentiments marking a shift towards less negativity and more neutrality. Sentiments by city showed most tweets in both periods coming from Riyadh and Jeddah in Saudi-Arabia, and from Salt in Jordan. Despite the limitations of the study, the change in sentiments detected by the study may suggest more vaccine acceptance which raises some hope and perhaps a higher vaccine uptake in the future. The sentiments by city findings may help in the design of future research.

PMID 43053887
阅读全文 →
PubMedNPJ vaccines2026-11-19

SARS-CoV-2 RBD fusion ameliorates enhanced disease induced by RSV G CCD mRNA vaccine in BALB/c mice.

Sun Yufang Y, Xie Ying Y, Liu Lian L, Yang Huijie H et al.

Respiratory syncytial virus (RSV) is a primary pathogen responsible for lower respiratory tract infections in both infants and the elderly. However, vaccine development has been consistently hampered by the risk of vaccine-enhanced disease (VED), while the role of the RSV attachment (G) glycoprotein has long been overlooked. Using an mRNA vaccine platform, this study systematically evaluated the roles of two critical RSV G protein domains-the central conserved domain (CCD) and the mucin-like domains-in mediating immune protection and VED. Results indicate that the mucin-like domains confer no protection and induce marked VED. Surprisingly, although CCD immunization elicits potent humoral immunity and significantly reduces viral load, it also induces Th2-biased responses and exacerbates pulmonary inflammation following RSV challenge. However, fusion of CCD with the receptor-binding domain (RBD) of SARS-CoV-2 in an mRNA vaccine (CCD + RBD) successfully redirected the Th2-biased immune responses toward a balanced Th1/Th2 profile, while significantly attenuating CCD-induced immunopathology. CD8⁺ T-cell depletion and adoptive-transfer experiments further supported a contribution of RBD-responsive CD8⁺ T cells to the reduction in pathology. These findings provide proof of concept that heterologous antigen fusion can reshape CCD-associated immunopathology in a BALB/c RSV challenge model.

PMID 43052326
阅读全文 →
PubMedNPJ vaccines2026-11-19

Efficacy, safety, and biodistribution of intranasally delivered adenoviral COVID-19 vaccine in hamsters.

Laham-Karam N N, Mäkinen P P, Koivulehto E E, Gurzeler E E et al.

Coronavirus disease 2019 (COVID-19) continues to cause outbreaks around the world despite the vast COVID-19 vaccination programs. Thus, it is important to continue developing better vaccines to protect vulnerable populations. Here, we studied the efficacy, safety, persistence and biodistribution of an adenovirus-based COVID-19 vaccine delivered intranasally. Our results confirmed that mucosal delivery leads to effective protection against infection in hamsters. A comparative study of different adenoviral vectors demonstrated that specifically Ad5-S-3M, expressing the SARS-CoV-2 spike glycoprotein ectodomain with inclusion of three common receptor binding domain mutations, induced a robust humoral immune response and effectively protected hamsters from SARS-CoV-2 infection. In addition, longitudinal analysis of vaccinated hamsters' tissues demonstrated durable vaccine transgene expression and persistent vector DNA in the nasal turbinates. This persistence may be beneficial in increasing the duration of immunity. Expression of the S-3M did not cause any aberrant changes in the hamster tissues and resulted in very few changes in cellular mRNA expression in target tissues. Safety and biodistribution assessment demonstrated restricted non-target tissue distribution of intranasally delivered vector and no significant changes in clinical blood chemistry, underlining the safety of the vaccine. These results further support that intranasal delivery is a promising approach for mucosal vaccine administration against respiratory infection pathogens and extend our knowledge of Adeno-vector persistence.

PMID 43052363
阅读全文 →
PubMedWorld journal of clinical cases2026-11-19

Correction to: Rectal cancer combined with abdominal tuberculosis: A case report.

Liu Pei-Gen PG, Chen Xiang-Fan XF, Feng Pan-Feng PF

[This corrects the article DOI: 10.12998/wjcc.v10.i31.11523.].

PMID 43053752
阅读全文 →
PubMedWellcome open research2026-11-19

Impact of personalised risk predictions on preventive treatment initiation in tuberculosis.

Rose-Key Rubin R, Gupta Rishi R, Noursadeghi Mahdad M

Preventive treatment for clinically latent Mycobacterium tuberculosis (Mtb) infection has low uptake, partly due to poor individual risk stratification. We evaluated whether personalised tuberculosis (TB) risk prediction influenced treatment initiation. We undertook a retrospective service evaluation at a single TB clinic in London May 2022-September 2024, in which the PERISKOPE-TB risk prediction model was presented within consultations with patients eligible for preventative treatment for clinically latent Mtb infection. We then examined the association between predicted risk and treatment acceptance using logistic regression, with restricted cubic splines to account for a non-linear relationship. Results are presented as an odds ratio (OR) with 95% confidence intervals (CI's). 283 patients were included in the evaluation, where 62% initiated treatment. Higher predicted TB risk was associated with increased treatment initiation; each 1% increase in risk more than doubled the odds of acceptance (OR 2.12, 95% CI 1.59-2.89). Personalised risk prediction may improve targeting and uptake of preventive TB treatment in those that need it the most.

PMID 43053890
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tuberculosis vaccine (Mw)